Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

被引：0
|
作者：
Kilickap, S. [1 ]
Sezer, A. [2 ]
Gumus, M. [3 ]
Bondarenko, I. [4 ]
Ozguroglu, M. [5 ]
Gogishvili, M. [6 ]
He, X. [7 ]
Gullo, G. [7 ]
Rietschel, P. [7 ]
Quek, R. G. [7 ]
机构：
[1] Istinye Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey
[2] Baskent Univ, Dept Med Oncol, Adana, Turkey
[3] Istanbul Medeniyet Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey
[4] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[5] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey
[6] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia
[7] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; patient-reported outcomes; cemiplimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.15-12
引用
收藏
页码：S125 / S126
页数：2
相关论文
共 50 条
  • [21] EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%
    Sriuranpong, V.
    Altundag, O.
    Clingan, P.
    Rizvi, N.
    Frontera, O. Aren
    Sezer, A.
    Paydas, S.
    Shavdia, M.
    Bondarenko, I.
    Gladkov, O.
    Lee, S.
    Li, S.
    Snodgrass, P.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial
    Makharadze, T.
    Quek, R. G.
    Melkadze, T.
    Gogishvili, M.
    Ivanescu, C.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Moreno-Jaime, B.
    Passalacqua, R.
    Konidaris, G.
    Rietschel, P.
    Gullo, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1414 - S1414
  • [23] EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC
    Gogishvili, M.
    Mobashery, N.
    Makharadze, T.
    Navarro, M.
    Snodgrass, P.
    Chen, H.
    Lowy, I.
    Rietschel, P.
    Lee, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S649 - S649
  • [24] Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3
    Makharadze, Tamta
    Quek, Ruben G. W.
    Melkadze, Tamar
    Gogishvili, Miranda
    Ivanescu, Cristina
    Giorgadze, Davit
    Dvorkin, Mikhail
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    Gessner, Christian
    Moreno-Jaime, Brizio
    Passalacqua, Rodolfo
    Konidaris, Gerasimos
    Rietschel, Petra
    Gullo, Giuseppe
    CANCER, 2023, 129 (14) : 2256 - 2265
  • [25] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Jaime, B. Moreno
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1567 - S1568
  • [26] EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1388 - S1388
  • [27] Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)
    Rueckert, A.
    Faehling, M.
    Fischer, J. R.
    Laack, E.
    Reck, M.
    Schulz, C.
    Wolff, T.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 214 - 214
  • [28] EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1182 - S1183
  • [29] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Moreno-Jaime, B.
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G. W.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1328 - S1328
  • [30] Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
    Bondarenko, I.
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Mcginniss, J.
    Pouliot, J.
    Lee, S.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S951 - S951
12345